Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Liabilities and Shareholders Equity (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Liabilities and Shareholders Equity for 7 consecutive years, with $225.2 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 43.26% to $225.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, down 37.96% year-over-year, with the annual reading at $225.2 million for FY2025, 43.26% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $225.2 million at Pliant Therapeutics, down from $276.6 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $597.9 million in Q1 2023, with the low at $184.6 million in Q2 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $365.8 million, with a median of $347.7 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity surged 211.39% in 2023, then tumbled 43.26% in 2025.
  • Over 5 years, Liabilities and Shareholders Equity stood at $221.2 million in 2021, then skyrocketed by 58.49% to $350.6 million in 2022, then skyrocketed by 46.07% to $512.2 million in 2023, then decreased by 22.49% to $396.9 million in 2024, then plummeted by 43.26% to $225.2 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $225.2 million, $276.6 million, and $299.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.